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Abstract 
Background: Receptor tyrosine kinase, c-Kit (CD117) plays a pivotal role in the maintenance and expansion of 
hematopoietic stem/progenitor cells (HSPCs). Additionally, over-expression and/or mutational activation of c-Kit have 
been implicated in numerous malignant diseases including acute myeloid leukemia. However, the translational regu-
lation of c-Kit expression remains largely unknown.
Methods and results: We demonstrated that loss of Pim1 led to specific down-regulation of c-Kit expression in 
HSPCs of Pim1−/− mice and Pim1−/−2−/−3−/− triple knockout (TKO) mice, and resulted in attenuated ERK and STAT3 
signaling in response to stimulation with stem cell factor. Transduction of c-Kit restored the defects in colony forming 
capacity seen in HSPCs from Pim1−/− and TKO mice. Pharmacologic inhibition and genetic modification studies using 
human megakaryoblastic leukemia cells confirmed the regulation of c-Kit expression by Pim1 kinase: i.e., Pim1-specific 
shRNA knockdown down-regulated the expression of c-Kit whereas overexpression of Pim1 up-regulated the expres-
sion of c-Kit. Mechanistically, inhibition or knockout of Pim1 kinase did not affect the transcription of c-Kit gene. Pim1 
kinase enhanced c-Kit 35S methionine labeling and increased the incorporation of c-Kit mRNAs into the polysomes 
and monosomes, demonstrating that Pim1 kinase regulates c-Kit expression at the translational level.
Conclusions: Our study provides the first evidence that Pim1 regulates c-Kit gene translation and has important 
implications in hematopoietic stem cell transplantation and cancer treatment.
Keywords: Receptor tyrosine kinase, c-Kit, PIM kinase, Serine/threonine kinase, Translation, Regulation, 
Hematopoiesis, Hematopoietic stem cells, Hematopoietic progenitor cells
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Background
c-Kit receptor (CD117), a member of the type III trans-
membrane receptor tyrosine kinase (RTK) family, plays 
an essential role in fetal and adult hematopoiesis [1–3]. 
When binding to its ligand, stem cell factor (SCF), c-Kit 
receptor dimerizes and phosphorylates at tyrosine resi-
dues, leading to the activation of the mitogen activated 
protein (MAP) kinase cascade (cRaf/Mek/Erk), the JAK/
STAT pathway, and the phosphoinositide-3 (PI-3) kinase 
signaling events [4]. Additionally, overexpression or acti-
vating mutation of c-Kit is implicated in the pathogenesis 
of many human cancers including acute myeloid leuke-
mia (AML) [5–7]. Because of the important roles of c-Kit 
in many physiological and pathological processes, there 
have been extensive studies undertaken to understand 
its transcriptional regulation, signal pathways, receptor 
dimerization, and protein degradation [8–11]. However, 
currently very little is known about the translational reg-
ulation of c-Kit.
Proviral insertion in murine lymphoma (Pim) kinases 
are a small family of serine/threonine kinases, and have 
3 isoforms (Pim1, Pim2, and Pim3) [12–15]. Pim kinases 
are oncogenic in several hematological malignancies 
including acute leukemia and lymphoma [12–15]. Fur-
thermore, Pim kinases are involved in the regulation of 
hematopoiesis [16–18]. We have recently demonstrated 
that Pim1 kinase regulates the biologic function and 
number of murine HSPCs [17, 18]. How Pim1 regulates 
murine hematopoiesis remains to be determined. Herein 
we reported the role and the molecular mechanisms of 
Open Access
Experimental Hematology & 
Oncology
*Correspondence:  yubin.kang@duke.edu 
5 Division of Hematologic Malignancies and Cellular Therapy, Department 
of Medicine, Duke University, DUMC 3961, Durham, NC 27710, USA
Full list of author information is available at the end of the article
Page 2 of 8An et al. Exp Hematol Oncol  (2016) 5:31 
Pim1 in regulating c-Kit expression in murine HSPCs 
and in human leukemia cells.
Methods
Cell lines
Human megakaryoblastic leukemia Molm-16 cells were 
grown in RPMI1640 medium supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. 
Human embryonic kidney (HEK) 293 cells were grown 
in DMEM high glucose medium supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. All 
the cells were cultured at 37 °C with 5% CO2.
Mice
Pim single knockout (KO) mice (Pim1−/−, Pim2−/−, and 
Pim3−/− mice), Pim triple (Pim1−/−Pim2−/−Pim3−/−) KO 
mice (TKO), and Pim1 transgenic (Pim1-Tx) mice have 
been described previously [17, 18]. All our animal studies 
were performed at Medical University of South Carolina 
(MUSC) and were in accordance with MUSC Institutional 
Animal Care and Use Committee approved- procedures.
Antibodies
Antibodies used for flow cytometry analyses, i.e., APC-
conjugated anti-mouse c-Kit (CD117) antibody (2B8), 
PE-conjugated anti-mouse Sca-1 antibody (E13-161.7), 
PE-conjugated anti-human c-Kit antibody (YB5.B8), 
APC-conjugated anti-human c-Kit antibody (YB5.B8), 
phospho-ERK antibody (Thr202/Tyr204), and phos-
pho-STAT3 antibody (pY705) were purchased from BD 
Pharmingen (San Diego, CA). Antibodies used for immu-
noblot analyses, i.e., anti-c-Kit antibody (D13A2), anti-
phospho-S6 antibody, anti-phospho-ERK antibody, eIF4B 
antibody, phospho-eIF4B (Ser406) antibody, and phos-
pho-eIF4B (Ser422) antibody were obtained from Cell 
signaling (Beverly, MA). Anti-β-Actin antibodies were 
purchased from Sigma-Aldrich (St. Louis, MO).
Reagents
Murine recombinant stem cell factor (SCF), human 
recombinant SCF, and Aqua Live/dead fixable dye were 
purchased from Invitrogen (Grand Island, NY). Hoe-
chst 33342 and hexadimethrine bromide (polybrene) 
were purchased from Sigma-Aldrich (St. Louis, MO). 
Magnetic murine lineage cell depletion kit was pur-
chased from Miltenyi Biotec (Auburn, CA). Trans-Len-
tiviral shRNA Packaging Kit with Calcium Phosphate 
(TLP5913) was purchased from Thermo Scientific 
(Pittsburgh, PA). GNE568 (a Pim 1 and 3 inhibitor) and 
GNE652 (a pan Pim inhibitor) were kindly provided by 
Dr. Allen Ebens at Genenetech Inc. (San Francisco, CA). 
SGI-1776 and CX-6258, both of which are pan Pim inhib-
itors, were purchased from Selleckchem (Houston, TX).
Flow cytometry analysis
For the measurement of side population (SP) cells, bone 
marrow (BM) cells were harvested from the femurs and 
tibias of different genotypes of mice. Red blood cells 
(RBCs) were depleted using ACK lysis buffer. The RBC-
depleted BM cells were enriched for Lin− cells using 
murine lineage cell depletion kit. Lin− cells were first 
labeled with c-Kit antibody and Scal-1 antibody and then 
stained with Hoechst 33342 dye as previously described 
[19]. Briefly, Hoechst 33342 at a final concentration of 
5 µg/ml was added to the cells (106 cells/ml), and the cells 
were incubated at 37 °C for 90 min. At the end of incuba-
tion, the cells were washed with PBS and analyzed within 
2 h on MoFlo flow cytometer (Beckman).
For the measurement of c-Kit surface expression in 
cell lines after drug treatment or gene transfer, the cells 
were stained with human PE-conjugated c-Kit antibody 
or APC-conjugated c-Kit antibody followed by live/dead 
dye staining.
For phospho-flow analysis, a previously described 
method was used with modifications [20]. Briefly, BM 
Lin− cells were first starved in serum free RPMI1640 
media for 30  min followed by 10  min stimulation with 
pre-warmed media containing SCF at a final concentra-
tion of 100  ng/ml for 10  min. The cells were then fixed 
in paraformaldehyde (a final concentration of 1.6%) for 
10 min. The cells were processed for surface staining, per-
meabilization with acetone, and staining with phospho 
antibodies. All flow cytometry data were analyzed using 
FlowJo software (TreeStar, Inc., Ashland, OR, USA).
Lentivirus production and gene transduction
The production and gene transduction of lentiviruses 
encoding shRNA against human Pim-1 or control shRNA 
were performed as described previously [21]. For the 
production of lentiviral vector encoding murine c-Kit, 
the open reading frame of murine c-Kit was PCR- ampli-
fied from the parental vector, pcDNA3-c-Kit (a gift from 
Dr. Harrison’s lab) [22]. The primers were: c-kit-XbaI-F: 
5′ TCGATCTAGAATGAGAGGCGCTCGCGGCGCCT 
G-3′, and c-kit-XbaI-R: 5′-GCGGTCTAGATCAGGC 
ATCTTCGTGCACGAGCAG-3′. The PCR product 
was subcloned into FU-CRW lentiviral vector [23]. The 
clones were sequenced and the clone with right c-Kit ori-
entation was used for the lentiviral production and titer 
determination as described previously [24].
Colony‑forming unit (CFU) assay
Bone marrow CFU assays were performed as previously 
described [25]. BM cells were harvested from wildtype 
mice, Pim1−/− mice, Pim2−/− mice, or TKO mice. RBC-
depleted BM cells were transduced with c-Kit FU-CRW 
or control FU-CRW lentiviruses by centrifugation at 
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3000×g for 90 min in the presence of 8 µg/ml polybrene. 
The cells were then plated in triplicates in complete 
M3434 methylcellulose medium (Stem Cell Technolo-
gies) following the manufacturer’s instructions (30,000 
cells per well) on 6-well plates. The number of CFUs-
GM, BFUs-E and CFUs-GEMM was counted at days 7, 9, 
and 12, respectively.
Western blot analysis
Following drug treatment or lentiviral transduction, cells 
(Molm-16 or HEK293 cells) were harvested, washed 
with PBS, and re-suspended in lysis buffer A containing 
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 1% Sodium deoxycholate, and 0.1% 
SDS. The cells were further lysed by brief sonication. 
The lysates were centrifuged at high speed for 10 min to 
remove cell debris. Total protein was quantified using DC 
protein assay kit (Bio Rad) with BSA for standard curve. 
Approximately 20  μg protein was loaded and run on 
SDS PAGE. The proteins were transferred onto nitrocel-
lulose membrane. The membrane was blocked with 5% 
milk in Tris-Buffered Saline containing 0.05% of Tween 
20 (TBST) and primary antibodies were applied with 1% 
BSA in TBST for overnight at 4  °C with gentle rocking. 
The membrane was then probed with HRP-conjugated 
secondary antibody and developed using Pierce ECL 
substrate.
Polysome profiling and RT‑PCR analysis
Human embryonic kidney 293T cell extracts used for 
polysome gradient centrifugation were prepared as 
previously described [26–28]. In brief, 5  ×  106 HEK 
cells transduced with control lentiviral vector (HEK-
Fu-Ctl) or Pim1-over-expressing lentiviral vector 
(HEK-Fu-Pim1) were cultured in 10-mm culture dishes 
and harvested after replacing the culture media with 
fresh media containing cycloheximide (Sigma, 100 μg/
ml) for 15  min. Cells were washed with PBS and then 
directly lysed in TMK100 buffer (10  mM Tris-HCl 
(pH 7.4), 100  mM KCl, 5  mM MgCl2, 1% (v/v) Triton 
X-100, 0.5% w/v deoxycholate, 2 mM dithiothreitol) on 
ice for 20 min. The lysates were centrifuged for 15 min 
at 10,000×g at 4 °C, and the supernatants were layered 
on top of linear 10–50% (w/v) sucrose gradients. Cen-
trifugation was carried out in a Beckmann SW41Ti 
Rotor at 35,000 rpm for 3 h at 4  °C. Polysome profiles 
were monitored by absorbance at 254 nm (A254). RNA 
from each fraction was isolated by Trizol extraction. 
One-step RT-PCR was performed using the MyTaq™ 
One-Step RT-PCR Kit (Bioline) on an Eppendorf Mas-
terCycler. All primers were designed and synthesized 
by Invitrogen.
35S methionine labeling assay
Human embryonic kidney 293T cells transduced with 
control lentiviruses or Pim1-overexpressing lentivi-
ruses were labeled with 20 μCi of 35S methionine per ml 
(Easytag Express Protein Labeling Mix, PerkinElmer) in 
RPMI1640 without cold methionine for 1 h, washed twice 
with PBS, and lysed in lysis buffer A. Cell lysates were 
centrifuged at 13,000×g for 10  min. The supernatant 
was collected and immunoprecipitation was performed 
with c-Kit antibody. Immunoprecipitated proteins were 
resolved by SDS-polyacrylamide gel and processed on 
SDS gel. Newly synthesized 35S methionine-c-Kit was vis-
ualized after exposure to X-AR films and then analyzed 
by a liquid scintillator (Beckman 6500).
Statistical analysis
Values reported and shown in graphical displays are 
mean +/− standard error of the mean (SEM) except 
where noted. Comparisons of mean expression across 
groups were made using two-sample t-tests.   p  value 
< 0.05 was used to denote significance.
Results and discussion
We recently reported that Pim1, but not Pim2 or Pim3, 
plays a major role in the regulation of normal murine 
HPSC function [17, 18]. To determine the roles of Pim 
kinases in the regulation of c-Kit expression, we analyzed 
c-Kit level in lineage negative (Lin−) bone marrow (BM) 
cells isolated from age-matched wildtype (WT), Pim1−/−, 
Pim2−/−, Pim3−/−, Pim1−/−2−/−3−/− triple knockout 
(TKO) mice, and Pim1 transgenic mice (Pim1-Tx). Com-
pared to WT Lin- BM cells, Lin- BM cells from Pim1−/− 
mice and Pim TKO mice showed a reduced level of c-Kit 
expression, whereas no changes in c-Kit expression were 
observed in Lin- BM cells from Pim2−/− or Pim3−/− mice 
(Fig. 1a). Conversely, Pim1-Tx mice showed an enhanced 
c-Kit expression (Fig.  1a). Additionally, c-Kit expres-
sion in murine hematopoietic stem cells (HSCs) defined 
by Hoechst 33342 side population (SP) showed similar 
changes [19]: i.e., compared to WT SP cells, the SP HSCs 
from Pim1−/− and Pim TKO mice had reduced levels 
of c-Kit expression, whereas no changes was observed 
in Pim2−/− SP cells (Fig.  1b). The effect of Pim1 on 
murine HSPC c-Kit expression is c-Kit-specific, because 
Pim1 deletion did not affect the expression of Sca-1 
or Flt3 (a member of type III RTK family) in Lin− BM 
cells (Fig. 1c). Further supporting the reduction in c-Kit 
expression level, p-ERK and p-STAT3 following SCF 
stimulation were significantly decreased in the HSPCs 
isolated from Pim TKO mice compared to those from 
age-matched WT mice (Fig.  1d). Taken together, these 
data demonstrated an important role of Pim kinases, in 
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particular Pim1 kinase, in regulating c-Kit expression in 
murine HSPCs.
Hematopoietic stem/progenitor cells from Pim1−/− 
and TKO mice had defects in CFUs as well as in their 
self-renewal and long-term repopulating capacity [17, 
18]. To determine if the down-regulation of c-Kit expres-
sion contributes to the hematopoietic defects seen in 






























































Fig. 1 Pim1 regulates c-Kit expression in murine HSPCs. a c-Kit expression is down-regulated in HSPCs from Pim1−/− and Pim TKO mice. Bone mar-
row cells were harvested from age-matched WT, Pim1−/−, Pim2−/−, Pim3−/−, Pim TKO, or Pim1 transgenic (Pim1-Tx) mice. Lineage negative (Lin−) 
cells were enriched and stained with PE-conjugated c-Kit antibody. The expression of c-Kit was analyzed by flow cytometry. FACS contour plots 
were shown. Data represent 3 independent experiments (>3 mice per group in each experiment). b c-Kit expression is down-regulated in SP cells 
from Pim1−/− and Pim TKO mice. BM Lin- cells obtained from WT, Pim1−/−, Pim2−/− and Pim TKO mice were stained with Hoechst 33342 followed 
by c-Kit antibody surface staining. The histograms of c-Kit expression on side population (SP) cells were shown. Data represent 2 independent 
experiments. c The expression of Sca-1 and Flt3 was not affected in HSPCs from Pim1−/− and Pim TKO mice. Top panel: BM Lin− cells were harvested 
from WT, Pim1−/−, Pim2−/−, or Pim TKO mice and stained with PE-conjugated Sca-1 antibody. FACS contour plots of Scal-1 were shown. Bottom 
panel: BM Lin− cells were harvested from WT, Pim1−/−, Pim2−/−, or Pim TKO mice and stained with Flt3 (CD135) antibody. Histogram overlay plots of 
Flt3 were shown. Data represent 3 independent experiments. d The c-Kit receptor signaling in response to SCF stimulation was reduced in HSPCs 
from Pim TKO mice. BM Lin- cells obtained from WT or Pim TKO mice were stimulated with SCF (final concentration of 100 ng/ml) for 10 min and 
then co-stained with Scal-1 antibody, c-Kit antibody, and p-ERK/p-STAT3 antibody as described in “Methods and materials” section. The level of 
p-ERK or p-STAT3 was gated on LSK cells. MFI mean fluorescent intensity. Data represent 2 independent experiments
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Pim2−/− mice, TKO mice or WT mice with c-Kit express-
ing lentiviral vector (Fu-c-Kit) or control vector (Fu-Ctl). 
CFUs were then measured. Transduction with c-Kit 
restored the impaired colony- forming ability (CFUs-
GM, BFUs-E and CFUs-GEMM) seen with Pim1−/− mice 
and TKO mice (Fig. 2), indicating that Pim1 kinase regu-
lates murine hematopoiesis at least in part through con-
trolling c-Kit expression. Over-expression of c-Kit did 
not affect the CFUs in Pim2−/− cells (Fig. 2).
We next performed pharmacologic and genetic studies 
using leukemia cell lines to further validate the regulation 
of c-Kit by Pim1 kinase. Molm-16, a megakaryoblastic 
leukemia cell line was used because in our pilot screen-
ing this cell line was found to have high level of c-Kit 
expression (data not shown). We found that treatment 
with GNE568 (a Pim1 and Pim3 duel kinase inhibitor) or 
GNE652 (a pan-Pim kinase inhibitor) resulted in reduced 
level of c-Kit expression in Molm-16 cells by west-
ern immunoblot (Fig.  3a) and flow cytometry (Fig.  3b). 
Additionally, specific knockdown of Pim1 by shRNA led 
to reduced c-Kit expression (Fig.  3c), and completely 
blocked SCF- induced ERK phosphorylation (Fig. 3c, d). 
pS6, an indicator for mTOR pathway and a downstream 
target of Pim, was used to validate the effectiveness of 
Pim inhibition with shRNA. Furthermore, exogenous 
over-expression of Pim1 resulted in increased level of 
c-Kit expression in HEK293 T cells transfected with 
Pim1-overexpression plasmid (Fu-Pim-1) (Fig. 3e). These 
studies further demonstrated the regulation of c-Kit 
expression by Pim1 kinase.
We examined the mechanisms through which Pim1 
kinase regulates c-Kit expression. No significant 
difference in c-Kit mRNA level was observed in BM cells 
derived from WT mice, Pim1−/− mice, TKO mice, and 
Pim1 Tx mice. Additionally, treatment with Pim inhibi-
tors did not affect c-Kit mRNA level (data not shown), 
suggesting that Pim1 kinase does not regulate c-Kit 
expression at the transcriptional level. We then deter-
mined if c-Kit is translationally regulated by Pim1 kinase. 
To this end, we transfected HEK293T cells with Pim1-
expressing plasmid or control plasmid and performed 
35S methionine-labeling assay. As shown in Fig. 4a, over-
expression of Pim1 increased 35S methionine labeled 
c-Kit level, suggesting that Pim1 kinase stimulates new 
c-Kit protein synthesis via enhanced translation. To fur-
ther determine the effects of Pim1 on c-Kit gene trans-
lation, we fractioned ribosomes of HEK293 T cells 
transduced with control lentiviral vector (Fu-Ctl) or Pim1 
overexpressing lentiviral vector (Fu-Pim1) and measured 
c-Kit RNA incorporation in polysomes and monosomes. 
As shown in Fig. 4b, more c-Kit RNA was seen in ribo-
somes of Pim1-transduced HEK293 T cells compared 
to those of control vector-transduced HEK293 T cells. 
Eukaryotic translation initiation factor 4B (eIF4B) plays 
an important role in the translation initiation [29]. When 
phosphorylated on Ser422, eIF4B enhances the binding 
of mRNA to the 43S preinitiation complex. To examine 
the effects of Pim inhibitors on the phosphorylation of 
eIF4B, we treated Molm-16 cells with 2 different pan-
Pim inhibitors (SGI1776 and CX6528), and measured 
phosphorylated eIF4B at Ser406 or Ser422. As shown in 
Fig.  4c, Pim inhibition down-regulated the phosphoryl-
ated eIF4B (Ser422). Taken together, these data demon-
strated that Pim1 kinase regulates c-Kit gene translation.
Fig. 2 Lentiviral transduction of c-Kit restores the defects in colony forming units in Pim1−/− and Pim TKO BM cells. BM cells isolated from WT, 
Pim1−/−, Pim2−/−, or Pim TKO mice were transduced with control lentiviruses (Fu-CRW-Ctl) or c-Kit-expressing lentiviruses (Fu-CRW-c-Kit) as 
described in “Methods and materials” section. The transduced cells were plated in Methocult M3434 for colony forming assay (30,000 cells/well) on 
6-well plates. CFUs (CFU-GM, BFU-E and CFU-GEMM) were quantified and shown. (*p<0.05, ** and ##p<0.01). Data represent 3 independent experi-
ments
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Conclusion
Our current  study demonstrates an important role of 
Pim1 kinase in the regulation of c-Kit in murine HSPCs 
and in human megakaryoblastic leukemia cell line. Our 
results suggest that this regulation occurs at transla-
tion level. These data are consistent with recent findings 
that Pim1 kinase regulates gene translation of c-MET 
in prostate cancer [27] and PDGFR in prostate stromal 
fibroblasts [28]. Pim kinases have been shown to regu-
late translation through the phosphorylation of PRAS40 
[30], TSC2 [31], and 4E-BP1 [32], leading to stimulation 
of mTOR activity and enhancing 5’Cap induced transla-
tion [33].
Our study has several important implications. Our 
findings provide new insight into the regulation of 
hematopoiesis. Furthermore, because of the impor-
tant roles of Pim kinase in hematopoiesis, it is expected 
that Pim inhibitors will cause bone marrow suppres-
sion, and thus hematological parameters will need to 
be monitored closely during clinical trials using Pim 
inhibitors for cancer treatment [34]. On the other hand, 






















Fig. 3 Pim1 regulates c-Kit expression in Molm-16 cells. a Pim kinase inhibitors down-regulated c-Kit expression in Molm-16 cells. Molm-16 cells 
were treated with DMSO, Pim1/3 inhibitor GNE568 (G568, 3 μM) or pan-Pim inhibitor GNE652 (G652, 1 μM) for 24 h. The cells were then collected 
for immunoblot. b Pim kinase inhibitors down-regulated c-Kit expression in Molm-16 cells. Molm-16 cells were treated as described in a and then 
stained with c-Kit antibody followed by FACS analysis. Data represent 2 independent experiments. c shRNA knockdown of Pim1 down-regulated 
c-Kit expression and signaling. Molm-16 cells were transduced with lentiviruses expressing control shRNA+eGFP (sh-Ctl) or expressing Pim1-spe-
cific shRNA+eGFP (sh-Pim1). GFP positive cells were sorted by FACS sorting and treated with or without 100 ng/ml SCF for 10 min. The cells were 
then collected for immunoblot. Data represent 2 independent experiments. d shRNA knockdown of Pim1 down-regulated c-Kit signaling. Molm-16 
cells transduced with shRNA as described in c were stained for p-ERK and analyzed by flow cytometry analysis. One of the representative FACS 
histograms of p-ERK expression was shown. Blue without SCF treatment, Red with SCF treatment. MFI mean fluorescence intensity. Data represent 
2 independent experiments. e overexpression of Pim1 up-regulated c-Kit expression. Molm-16 cells were transduced with lentiviruses expressing 
control+RFP (Fu-Ctl) or expressing Pim1+RFP (Fu-Pim1). Transduced, RFP positive cells were sorted by FACS sorting and immunoblot analysis was 
performed on the transduced cells. Data represent 2 independent experiments
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the pathogenesis of leukemia and several other hemato-
logical malignancies. Targeting Pim kinases could be an 
effective treatment strategy for decreasing this receptor 
in conditions where it drives malignant growth.
Abbreviations
HSCs: hematopoietic stem cells; HSPCs: hematopoietic stem/progenitor cells; 
SP: side population; RTK: receptor tyrosine kinase; SCF: stem cell factor; AML: 
acute myeloid leukemia; Pim: proviral insertion in murine lymphoma; WT: 
wildtype; KO: knockout mice; TPO: Pim1−/−2−/−3−/− triple knockout mice; Lin-: 
lineage negative; BM: bone marrow; CFU: colony-forming unit.
Authors’ contributions
NA conceived, performed most of the experiments, analyzed data, contrib-
uted to the writing of the manuscript; BC and JHS assisted with vector con-
struction, ribosome profiling and methionine labeling assay; HC performed 
c-Kit lentiviral production and contributed to the writing of the manuscript; 
AK provided animal colonies and contributed to the writing of the manuscript; 
YK conceived and designed the study and wrote the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Department of Pathology, University of Chicago, Chicago, USA. 2 Holl-
ings Cancer Center, Medical University of South Carolina, Charleston, USA. 
3 Department of Pharmaceutical & Biomedical Sciences, University of Georgia, 
Athens, USA. 4 The University of Arizona Cancer Center, University of Arizona, 
Tucson, USA. 5 Division of Hematologic Malignancies and Cellular Therapy, 
Department of Medicine, Duke University, DUMC 3961, Durham, NC 27710, 
USA. 
Acknowledgements
We thank Dr. Allen Ebens at Genentech Inc. for providing us reagents (GNE568 
and GNE652) for our study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets supporting the conclusion of this article are included within this 
article.
Ethics approval and consent to participate
Our animal studies were performed in accordance with Medical University 
of South Carolina (MUSC) Institutional Animal Care and Use Committee 
approved- procedures.
Funding
This work was supported by MUSC Hollings Cancer Center Startup Fund, Hol-
lings Cancer Center ACS IRG (YK), ASCO Conquer Cancer Foundation Career 
Development Award (YK), NHLBI K08HL103780 (YK), NCI P30CA138313-01S3 
(YK and AK), NCI R01CA197792 (YK), R01CA173200 (AK), R01CA172495 (HC), 
and DOD W81XWH-15-1-0507 (HC). The funding agents had no roles in the 
design of the study, in the collection, analysis and interpretation of data, and 
































Fig. 4 Pim1 regulates c-Kit gene translation. a Pim1 enhances the synthesis of new c-Kit protein. HEK 293 cells transfected with Fu-CRW-Ctl or Fu-
CRW-Pim1 were treated with cycloheximide (CHX, 100 µg/ml) for 3 h. The cells were then labeled with 35S methionine. Newly synthesized c-Kit was 
immunoprecipitated and separated by SDS-PAGE, and visualized by autoradiography (top panel). Aliquots of the cell lysates were run on SDS-PAGE 
and stained with Coomassie blue to be used for controlling the amount to protein loading (bottom panel). M protein molecular weight marker. Data 
represent 2 independent experiments. b Pim1 kinase enhances c-Kit RNA incorporation in ribosome fractions. HEK 293 cells were transduced with 
control lentiviruses (Fu-Ctl) or Pim1-expressing lentiviruses (Fu-Pim1). Light and heavy ribosome fractions were collected for 17 fractions (0.5 ml/
fraction) by sucrose gradient centrifugation. The Levels of c-Kit mRNA and β-actin mRNA in the fractions were measured by semi-quantitative 
RT-PCR assays and the products were run on agarose gel. c Pim inhibitors down-regulated the phosphorylation of eIF4B Ser422. Molm-16 cells 
were treated with DMSO or pan-Pim inhibitors (SGI1776 at 7 μM or CX6258 4 μM) for 24 h. The cells were harvested and immunoblot analyses were 
performed. Data represent 3 independent experiments
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